Atalanta secures $97m in Series B round to advance RNAi therapies

Atalanta Secures $97m In Series B Round To Advance RNAi Therapies

3 weeks from now

Jan 29, 2025  · Atalanta Therapeutics has secured oversubscribed $97m in Series B financing to propel the Phase I trials of its RNA interference (RNAi) treatments targeting KCNT1-related …

pharmaceutical-business-review.com

Atalanta Therapeutics Raises $97M In Series B Financing To …

3 weeks from now

Jan 29, 2025  · NEW YORK – Atalanta Therapeutics on Tuesday announced it had closed an oversubscribed Series B funding round with $97 million, which it will use to advance two RNA …

precisionmedicineonline.com

RNAi Biotech Atalanta Unveils $97M To Reach The Clinic In Two …

3 weeks from now

Jan 28, 2025  · An RNA interference (RNAi) therapy uses small pieces of non-coding RNA to block how certain genes are expressed. In 2018, Alnylam Pharmaceuticals’ Onpattro became the …

medcitynews.com

Atalanta Therapeutics Closes Oversubscribed $97 Million Series B ...

3 weeks from now

Jan 28, 2025  · BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today …

businesswire.com

Sanofi- And Novartis-backed Atalanta Loads Crossbow With $97M

3 weeks from now

Jan 28, 2025  · Atalanta loads crossbow with $97M, targeting neuro trial starts for 2 RNAi therapies By Gabrielle Masson Jan 28, 2025 7:00am Atalanta Therapeutics EQT Ventures …

fiercebiotech.com

Atalanta Gets $97 Million Series B To Target Neurological

3 weeks from now

Jan 28, 2025  · This series B brings the total financing Atalanta has raised since its launch to $262 million, according to Atalanta’s statement. Atalanta’s pipeline focuses on getting RNAi-based …

biospace.com

Atalanta Thera Closes $97 Million Series B Financing

3 weeks from now

Jan 28, 2025  · Boston, USA-based RNA focused biotech Atalanta Therapeutics today announced the completion of a $97 million Series B financing to support Phase I clinical trials of the …

thepharmaletter.com

Sanofi Joins $97M Bet On Atalanta's CNS-penetrating RNAi Drugs

3 weeks from now

Jan 28, 2025  · Atalanta Therapeutics has secured $97 million in series B financing to advance its RNAi therapeutics into their first clinical trials, with Sanofi Ventures and EQT Life Sciences co …

firstwordpharma.com

Atalanta Therapeutics Closes Oversubscribed $97 Million …

3 weeks from now

create meaningful new RNAi therapies, and Sanofi Ventures is glad to support Atalanta as they advance their pipeline.” ATL-201 is Atalanta’s investigational therapy for KCNT1-related …

sanofiventures.com

Atalanta Biotech: $97 Million For Advances In Rare Neurosciences

3 weeks from now

Jan 29, 2025  · Atalanta Therapeutics recently announced a funding round of $97 million, co-led by EQT Life Sciences and Sanofi Ventures, to support the development of two therapeutic …

globalsante.org

Atalanta Therapeutics Unveils $97M To Reach The Clinic In Two …

3 weeks from now

Jan 29, 2025  · The Boston-based startup also announced $97 million in financing to advance those programs to the clinic and support other CNS therapies in its pipeline. An RNA …

oodaloop.com

Atalanta Therapeutics Raises $97 Million To Advance RNAi Therapies …

3 weeks from now

Jan 30, 2025  · The company’s therapies are based on RNA interference, a process in which the expression of a gene of interest can be stopped. This is known as silencing. Atalanta’s ATL …

biopharma-reporter.com

Atalanta Therapeutics Closes Oversubscribed $97 Million Series B ...

3 weeks from now

BOSTON, January 28, 2025-- Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the …

vcaonline.com

Atalanta Raises $97M For Two RNAi Drugs; Helicore E... | DeepNewz

3 weeks from now

Jan 30, 2025  · Atalanta Therapeutics has successfully raised $97 million in a Series B funding round aimed at advancing two RNA interference (RNAi) drugs into human trials for rare …

deepnewz.com

Atalanta Loads Crossbow With $97M, Targeting Neuro Trial Starts For …

3 weeks from now

Jan 28, 2025  · Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small interfering RNA (siRNA) candidates in epilepsy and …

newsguard.ca

Atalanta Gets $97M Boost To Take Two SiRNAs Into Clinic For Rare …

3 weeks from now

Jan 28, 2025  · For five years, Atalanta Therapeutics operated with one investor. Now, F-Prime Capital is getting a bevy of financial support to propel two of the Boston biotech's RNAi drugs …

endpts.com

New Drug Candidate Works To Inhibit Both Tau Protein “Hotspots” …

3 weeks from now

Oct 3, 2024  · Atalanta Raises $97M to Advance Two Neuro-Targeting RNAi Therapies into the Clinic ... RI-AG03 is the only peptide aggregation inhibitor that inhibits aggregation of Tau by …

insideprecisionmedicine.com